Methemoglobinemia is a rare but potentially serious blood disorder that reduces the body’s ability to deliver oxygen to tissues. It occurs when hemoglobin, the protein in red blood cells responsible for carrying oxygen, is altered into a form called methemoglobin. Unlike normal hemoglobin, methemoglobin cannot efficiently bind or release oxygen. This leads to reduced oxygen delivery throughout the body, which can cause symptoms ranging from mild skin discoloration to life-threatening complications if not promptly treated. 

Although methemoglobinemia has been recognized in medicine since the 19th century, it continues to be clinically significant today. It may develop as a result of exposure to certain medications, chemicals, or environmental toxins, and in some cases it arises from inherited enzyme deficiencies. Distinguishing between acquired and congenital forms is important for understanding both prognosis and treatment. Because the condition can mimic other causes of low oxygen, recognizing its unique signs and symptoms is critical for timely diagnosis and care. 

This article provides a comprehensive overview of methemoglobinemia, including its causes, types, clinical features, diagnostic strategies, treatment, complications, prognosis, and prevention. By understanding its mechanisms and management, patients and healthcare professionals can work together to reduce risks and improve outcomes associated with this uncommon but serious disorder. 

Methemoglobinemia is defined as the presence of higher-than-normal levels of methemoglobin in the blood, usually above 1–2% of total hemoglobin. At levels greater than 10–15%, patients may begin to show signs of hypoxia, while levels above 70% can be fatal. Normally, red blood cells have systems—especially the NADH-dependent enzyme cytochrome b5 reductase—that reduce methemoglobin back to functional hemoglobin. When these systems are overwhelmed or deficient, methemoglobin accumulates, preventing proper oxygen delivery to the body. 

Methemoglobinemia can be categorized into two main types, and understanding these distinctions is crucial for guiding diagnosis and treatment. The acquired form develops when outside factors, such as drugs or chemicals, cause hemoglobin to oxidize. In contrast, congenital forms result from inherited enzyme deficiencies or genetic changes that make hemoglobin more vulnerable to oxidation. While both share similar clinical features, their causes and long-term implications differ significantly. Appreciating these differences helps healthcare providers determine the most effective management strategies. 

Acquired Methemoglobinemia 

• Caused by exposure to drugs, chemicals, or toxins that oxidize hemoglobin. 

• More common than the congenital form. 

Congenital Methemoglobinemia 

• Caused by inherited enzyme deficiencies or abnormal hemoglobin variants. 

• Includes cytochrome b5 reductase deficiency (Type I and Type II) and hemoglobin M disease. 

Acquired methemoglobinemia is more common than congenital cases and often results from exposure to medications or environmental chemicals. It is more frequently seen in infants under six months of age, as their enzyme systems are less mature and they are more vulnerable to nitrate exposure. Congenital forms are rare, occurring in approximately 1 in 1,000,000 individuals worldwide, though certain isolated populations have higher prevalence due to genetic inheritance. 

Methemoglobinemia may be caused by either external exposures (acquired) or inherited conditions (congenital). 

Acquired Causes 

• Medications and chemicals: benzocaine, prilocaine, lidocaine, nitrates, dapsone, sulfonamides, nitrobenzene, aniline dyes, chloroquine, phenazopyridine, nitroglycerin, sodium nitroprusside. 

• Environmental exposures: nitrate-contaminated water, fertilizers, aniline dyes, occupational exposure. 

• Medical conditions: sepsis, gastroenteritis, and infections that increase nitrate conversion in the gut. 

Congenital Causes 

Cytochrome b5 reductase deficiency: 

• Type I: limited to red blood cells, usually mild with lifelong cyanosis. 

• Type II: affects all tissues, leading to severe neurological issues. 

Hemoglobin M disease: caused by abnormal hemoglobin variants prone to oxidation, resulting in lifelong cyanosis. 

Hemoglobin normally carries oxygen when iron is in the ferrous (Fe²⁺) state. Oxidation of iron into the ferric (Fe³⁺) state creates methemoglobin, which cannot carry oxygen. This condition also increases the oxygen-binding tendency of normal hemoglobin, making it harder to release oxygen into tissues. Normally, less than 1–2% of hemoglobin exists in this form. When oxidant stress exceeds the body’s reduction capacity, or in infants with immature enzymes, methemoglobin builds up and impairs oxygen delivery. 

The symptoms of methemoglobinemia can present in a wide range of ways depending on how elevated the blood levels of methemoglobin become. At lower levels, people may notice only subtle changes, while higher concentrations lead to more pronounced and potentially dangerous effects. Early indicators often include unexplained cyanosis, or bluish discoloration of the skin and lips, that does not improve with oxygen therapy. Another classic finding is chocolate-brown colored blood, which is typically observed during lab testing or blood sampling. 

Symptoms by Methemoglobin Level: 

• <10%: Often asymptomatic, mild cyanosis may occur. 

• 10–20%: Noticeable cyanosis, chocolate-brown blood. 

• 20–30%: Headache, dizziness, rapid heartbeat, mild shortness of breath. 

• 30–50%: Fatigue, confusion, worsening shortness of breath, chest pain. 

• 50–70%: Severe neurological impairment, seizures, arrhythmias. 

• >70%: Life-threatening hypoxia, often fatal. 

Congenital forms: 

• Type I usually presents as lifelong cyanosis without other severe health problems. 

• Type II is more serious, with developmental delays and neurological impairment. 

Accurately diagnosing methemoglobinemia requires a combination of clinical awareness and targeted testing. Because the symptoms can resemble other causes of low oxygen, physicians rely on both physical findings and specialized laboratory studies to confirm the diagnosis. A key feature is the mismatch between apparent oxygen levels and the patient’s clinical presentation, which often raises suspicion. Establishing a correct diagnosis quickly is vital, since treatment decisions depend on recognizing this condition rather than assuming more common respiratory or cardiac problems. 

Laboratory Tests: 

• Arterial blood gas (ABG): Normal oxygen levels, but low oxygen delivery. 

• Pulse oximetry: Typically fixed around 85%, regardless of oxygen therapy. 

• Co-oximetry: Gold standard test; directly measures methemoglobin levels. 

• Blood color: Chocolate-brown appearance that does not change with oxygen. 

• Additional labs: CBC, electrolytes, lactate levels. 

Diagnostic Clues: 

• Discrepancy between normal ABG oxygen and low pulse oximetry. 

• Cyanosis that does not improve with supplemental oxygen. 

Differential Diagnosis: 

• Sulfhemoglobinemia 

• Hypoxia from lung or heart disease 

• Polycythemia 

• Central or peripheral cyanosis 

Management of methemoglobinemia is centered on restoring oxygen delivery and minimizing oxidative stress in the body. Because the severity of the condition can vary widely, treatment must be individualized based on both the underlying cause and the measured level of methemoglobin. Clinicians often begin with supportive care while investigating possible triggers such as drugs or environmental exposures. Once identified and addressed, targeted therapies can quickly reverse symptoms and help prevent further complications. 

General Principles: 

• Remove the triggering drug, chemical, or exposure. 

• Provide supplemental oxygen. 

• Monitor neurological and cardiac function. 

Specific Treatments: 

• Methylene Blue: First-line treatment if symptomatic or methemoglobin >20–30%. Standard dose: 1–2 mg/kg IV over 5 minutes, repeat if needed. Avoid in G6PD deficiency. 

• Ascorbic Acid (Vitamin C): Alternative reducing agent for mild cases or when methylene blue is not suitable. 

• Exchange Transfusion: Option for severe, refractory cases or G6PD-deficient patients. 

• Hyperbaric Oxygen Therapy: Rarely used, but may help in severe cases. 

• Hypoxic organ injury, especially brain and heart. 

• Cardiac arrhythmias. 

• Seizures. 

• Lactic acidosis. 

• Death in severe, untreated cases. 

With early diagnosis and treatment, particularly with methylene blue, most cases of acquired methemoglobinemia result in excellent outcomes and full recovery. In contrast, congenital Type I cases are generally benign, producing lifelong cyanosis without major health issues. Type II congenital cases, however, have a much poorer prognosis because they are linked to severe neurological impairment and developmental challenges. Prognosis therefore depends heavily on whether the condition is acquired or inherited, as well as the specific type of congenital involvement. Careful monitoring and timely treatment remain essential for improving long-term outcomes. 

For Acquired Methemoglobinemia: 

• Avoid overuse of topical anesthetics, especially in infants. 

• Carefully monitor medications known to cause the condition. 

• Test well water for nitrates in at-risk areas. 

For Congenital Methemoglobinemia: 

• Genetic counseling for families. 

• Education on avoiding oxidizing drugs and triggers. 

Methemoglobinemia is a rare but serious disorder that limits oxygen delivery in the body. Its causes include both inherited conditions and external exposures such as drugs and chemicals. Because symptoms can mimic other conditions, recognition of key signs—particularly cyanosis unresponsive to oxygen—is essential. With proper diagnosis and prompt treatment, most acquired cases resolve quickly, though congenital forms may require lifelong management. Preventive strategies, patient education, and continued research are key to reducing the risks associated with this condition. 

1. Wright RO, Lewander WJ, Woolf AD. Methemoglobinemia: etiology, pharmacology, and clinical management. Ann Emerg Med. 1999;34(5):646-656. 
2. Ash-Bernal R, Wise R, Wright SM. Acquired methemoglobinemia: a retrospective series of 138 cases at 2 teaching hospitals. Medicine (Baltimore). 2004;83(5):265-273. 
3. Percy MJ, Lappin TR. Recessive congenital methaemoglobinaemia: cytochrome b5 reductase deficiency. Br J Haematol. 2008;141(3):298-308. 
4. Skold A, Cosco DL, Klein R. Methemoglobinemia: pathogenesis, diagnosis, and management. South Med J. 2011;104(11):757-761. 
5. Umbreit J. Methemoglobin — it’s not just blue: a concise review. Am J Hematol. 2007;82(2):134-144.